Skip to main content
. 2023 Jul 26;21:222. doi: 10.1186/s12957-023-03107-5

Table 1.

Clinicopathologic characteristics of 460 nipple-sparing mastectomy procedures

N = 460
Age, year 48.3 ± 9.1
 < 40 75 (16.3)
 ≧ 40, < 60 329 (71.5)
 ≧ 60 56 (12.2)
Location
 Left 221 (48.1)
 Right 239 (51.9)
BMI (body mass index) 23.7 ± 3.7
 < 18 19 (4.1)
 18–24 271 (58.9)
 > 24 170 (37.0)
Surgical methods
 Conventional NSM 174 (37.8)
 Endoscopic-assisted NSM 195 (42.4)
 Robotic-assisted NSM 91 (19.8)
Specimen size, g (NA = 48) 327.1 ± 184.5
 < 180 66 (16.01)
 180–320 173 (41.99)
 320–450 93 (22.57)
 > 450 80 (19.41)
Surgical ALN staging method (NA = 46)
 SLNB 298 (71.9)
 SLNB + ALND 85 (20.6)
 ALND 31 (7.5)
Tumor size, cm (NA = 87) 2.5 ± 2.2
ALN metastasis on pathology (NA = 44)
 N0 290 (69.7)
 N1 96 (23.1)
 N2 24 (5.8)
 N3 6 (1.4)
Stage (NA = 64)
 0 87 (21.9)
 I 107 (27.1)
 II 157 (39.7)
 III 44 (11.1)
 IV 1 (0.2)
ER (NA = 76)
 Positive 320 (83.3)
 Negative 64 (16.7)
PR (NA = 78)
 Positive 270 (70.7)
 Negative 112 (29.3)
HER-2 (NA = 131)
 Positive 80 (24.3)
 Negative 249 (75.7)
Ki-67 (NA = 189)
 ≦ 14 139 (51.3)
 > 14 132 (48.7)
Pathology (NA = 3)
 DCIS 94 (20.6)
 IDC 261 (57.1)
 ILC 16 (3.5)
 LCIS 3 (0.6)
 Other 83 (18.2)
Operation time 224.2 ± 124.3
Reconstruction
 Yes 383 (83.3)
 No 77 (16.7)
Complication
 Yes 102 (22.2)
 No 358 (77.8)
Chemotherapy (NA = 31)
 Yes 174 (40.6)
 No 255 (59.4)
Radiotherapy (NA = 31)
 Yes 116 (27.1)
 No 313 (72.9)
Recurrence
 Yes 37 (8)
 No 423 (92)
Metastasis
 Yes 30 (6.5)
 No 430 (93.5)
Follow-up time (time since surgery) month 42.4 ± 32.5

BMI body mass index, ALN axillary lymph node, SLNB sentinel lymph node biopsy, ALND axillary lymph node dissection, NSM nipple-sparing mastectomy. ★IDC, IDC, IDC + ILC, IDC + LCIS, IDC + DCIS < 10%, IDC + DCIS (IDC + DCIS = IDC + DCIS, IDC + DCIS + LCIS). ★ILC, ILC, ILC + LCIS, ILC + DCIS. ★other, other cancer